LadRx Corp (LADXD)

[mr10001]

Guess Who Owns 36%

RXII $3.00 stock

Rodman & Renshaw initiates RXII with a Mkt Outperform and price target of $8. The firm considers RNA interference to be among the most significant recent discoveries in biology, and they believe that its translation into medicines could provide answers for multiple therapeutic areas, given the technology's potential to address diseases that are considered "undruggable" by currently available therapeutic modalities. The firm views RXII as being among a very small number of second-generation or "follow-on" young companies in the space, since it possesses the unique combination of singular focus on RNAi, top notch scientific advisors, and expertise in the development of RNA-based therapeutics. The firm believes that this combination of characteristics, make RXII part of a handful of companies with the potential to follow on a path similar to Alnylam in its early days, and a company that could eventually become one of the few early winners in the space of RNA-based therapeutics.